Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

BACKGROUND: Venetoclax with hypomethylating agents is a new standard of care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Haematol
Autors principals: DiNardo, Courtney D., Maiti, Abhishek, Rausch, Caitlin R., Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G., Kadia, Tapan M., Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C., Montalban-Bravo, Guillermo, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J., Takahashi, Koichi, Burger, Jan, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M., Thompson, Philip A., Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G., Wang, Sa A., Konopleva, Sergej, Chen, Zhining, Pierce, Sherry A., Ning, Jing, Qia, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S., Kantarjian, Hagop M., Konopleva, Marina Y.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549397/
https://ncbi.nlm.nih.gov/pubmed/32896301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(20)30210-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars